GOVXGeoVax, Inc.Finished
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Recurrent Head and Neck Cancer
15Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +14.8
A key executive is leaving
Since Nov 6, 2026 · was worth 15, fading over time
Worry score15
Score over time
- Stage
- Phase 1/2
- Patients
- 10 (final count)
- Started
- Feb 11, 2019
- Main results expected
- Dec 29, 2023
- Fully finished
- Dec 31, 2024
- Results posted
- Mar 20, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety Measures (Adverse Events and Laboratory Parameters) With Repeat Cycles of Treatment.
Measured over: up to 7 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 14.8, since 2026-11-06, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT03754933 · record last updated 2025-03-27 · checked 2026-11-09 15:47 UTC